A phase 1 study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies

Subjects

Subjects :

Gene isoform
Phosphoinositide 3-kinase
biology
business.industry
Cancer
Hematology
medicine.disease
Oncology
Phase (matter)
biology.protein
Cancer research
medicine
business
PI3K/AKT/mTOR pathway

Details

ISSN :

09237534

Volume :

28

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi...........aa16756976bd20b859dab95c60ac5eb4

Full Text :

https://doi.org/10.1093/annonc/mdx365.020